Post-marketing requirements of the US accelerated approval and European conditional marketing authorization during 2015-2020ZHANG Xiao-fang, BAI Xue, SUN Wan, WANG Feng-zhi, CHEN Si-yu, WU Yang-feng737-744
Preliminary study on the comprehensive protection system of intellectual property of innovative Chinese medicine:based on the empirical analysis of Lianhua Qingwen products manufactured by Yiling PharmaceuticalZHOU Jia, MAO Ji, XUE Jiao, HE Hua-shan745-751
Fezolinetant,a non-hormonal treatment for perimenopausal vasomotor symptomsXIAO Ran, DU Xiao-li752-755
New considerations for the risk-based initiation of drug registration clinical trial inspection from the perspective of regulatory scienceHE Hui, LIU Yi-di, ZHOU Gang756-760
Analysis of consultation on general technical issues in drug registration application in the Guangdong-Hong Kong-Macao Greater Bay AreaLI Lan-lan, TAN Meng-si, HUANG Xiao-long761-767
Evaluation consideration for clinical research and development of URAT1 inhibitors for goutSERI Ge-leng, AI Xing, ZHAO Bo-yuan, LI Yuan-hong, ZHAO Tian, ZHANG Jie768-773
Progress in application of on-line inspection technology in continuous tablet manufacturingLIANG Jun-jie, ZHANG Yao, PAN Hao-min, RAO Xiao-yong, LIU Wei, LUO Xiao-jian, HE Yan774-784
Efficacy and safety of Taizi Shenyue Capsules in the treatment of mild to moderate depressionXU Bao-yan, LIU Yuan-xin, YIN Xiao-li, ZHAO Jing-ping, WU Hai-shan, ZHANG Ke-rang, XIAO Wei-dong, HOU Dong-fen, LIU Ying, LI Cheng-gong, LI Le-hua792-797
Developmental status and considerations of global clinical trial systemsCHANG Feng-yuan, LIN Lin, TIAN Li-juan798-804